Calamine Lotion, cutaneous suspension

País: Irlanda

Idioma: anglès

Font: HPRA (Health Products Regulatory Authority)

ingredients actius:

Zinc oxide; Calamine

Disponible des:

Ovelle Limited

Codi ATC:

D02AB

Designació comuna internacional (DCI):

Zinc oxide; Calamine

Dosis:

15 %w/v + 5 percent weight/volume

formulario farmacéutico:

Cutaneous suspension

tipo de receta:

Product not subject to medical prescription

Área terapéutica:

Zinc products

Estat d'Autorització:

Marketed

Data d'autorització:

1992-10-14

Fitxa tècnica

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Calamine Lotion, cutaneous suspension.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Calamine 15% w/v
Zine Oxide 5% w/v
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Cutaneous Suspension.
Calamine Lotion is a pale pink lotion which separates on standing.
It has a faint characteristic odour.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Calamine Lotion is a mild astringent lotion recommended for the
topical treatment of mild skin irritation and
inflammation, including mild sunburn.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Calamine Lotion is applied topically to the affected area with cotton
wool and allowed to dry.
4.3 CONTRAINDICATIONS
Calamine Lotion is contraindicated in patients with a known
sensitivity to its ingredients.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
No adverse effects reported.
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
Zinc oxide is incompatible with benzylpenicillin. Zinc oxide reacts
slowly with fatty acid in oils and fats to produce the
corresponding fatty acid esters.
4.6 FERTILITY, PREGNANCY AND LACTATION
No adverse effects reported.
4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
No adverse effects reported.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_1_
_4_
_/_
_0_
_9_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_2_
_1_
_8_
_9_
_6_
_1_
_9_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.8 UNDESIRABLE EFFECTS
None reporte